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Summary
Background: The relationships between (1) serum concentration of cardiac troponin
T (cTnT) and clinical hemodynamic proﬁles, (2) cTnT versus B-type natriuretic pep-
tide (BNP) and long-term echocardiographic changes, and (3) cTnT versus BNP and
echocardiographic changes, and rates of adverse cardiac events, have not been well
elucidated.
Methods: Retrospective analysis of 100 consecutive patients with heart failure, left
ventricular ejection fraction <50%, and non-ischemic heart disease was performed.
Results: Baseline cTnT was ≥0.01 ng/ml in 30 patients. By multiple variable logistic
regression analysis, diabetes mellitus [DM; odds ratio (OR) 7.5; p = 0.014], serum
creatinine (OR 25.9; p = 0.0157), and pulmonary capillary wedge pressure (PCWP;
OR 1.12; p = 0.0214) were independent predictors of baseline elevation of cTnT. At a
follow-up of 40.6± 20.6 months, echocardiograms and cTnT and BNP measurements
were available in 93 patients, of whom 23 experienced an adverse cardiac event.
By multiple variable analyses, elevated cTnT at follow-up was negatively correlated
with echocardiographic improvements in cardiac function (OR 0.10; p = 0.019), and
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was a signiﬁcant predictor of adverse cardiac events after adjustment for covariables,
including follow-up BNP and echocardiographic changes (hazard ratio 5.6; p = 0.0046).
Conclusions: DM, serum creatinine, and PCWP were correlated with elevated baseline
serum cTnT concentrations. cTnT concentration during follow-up might be a surrogate
marker of heart failure.
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All results are presented as means± standard
deviation (S.D.). Continuous variables were com-
pared by factorial analysis of variance, and© 2009 Japanese Colleg
reserved.
Introduction
The blood concentrations of B-type natriuretic pep-
tide (BNP) are used as a marker of myocardial load,
and several studies have examined their diagnos-
tic and predictive value in patients suffering from
heart failure (HF) [1,2]. Moreover, the changes in
BNP that take place over time have been corre-
lated with long-term risk of adverse cardiac events
[3,4] and changes in cardiac function ascertained
by echocardiography [5,6]. On the other hand, the
serum concentrations of cardiac troponin (cTn) T
[7], a marker of myocyte injury, can be used to
risk stratify patients presenting with chronic [8—13]
or acute congestive HF [14,15]. However, the rela-
tionships between serum cTnT concentrations and
(1) clinical characteristics and measurements made
during baseline cardiac catheterization, (2) long-
term changes in echocardiographic cardiac function
with BNP concentrations as one of the confounding
variables, and (3) long-term clinical outcomes with
BNP concentrations and echocardiographic changes
as the confounding variables, have not been studied
in depth.
Patients and methods
Between January 2001 and June 2007, we
searched our database of elective diagnostic
cardiac catheterization, and identiﬁed 100 con-
secutive patients who had a <50% left ventricular
(LV) ejection fraction (EF) on ventriculography, in
absence of (a) history of myocardial infarction and
(b) >50% stenosis of any coronary artery. Patients
with congenital heart disease, aortic valve dis-
ease, mitral valve regurgitation requiring surgical
treatment, history of myocarditis, malignancy, con-
nective tissue disease or cardiac amyloidosis, and
patients undergoing hemodialysis were excluded
from this analysis. All study procedures were in
compliance with the institutional guidelines of
Hyogo Prefectural Amagasaki Hospital.Baseline data collection
In this retrospective analysis of a database of
patients with HF and non-ischemic heart dis-
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ase accumulated since 1995 [7—9], baseline
oncentrations of cTnT (3rd generation assays,
oche Diagnostics, Mannheim, Germany) and BNP
Shionogi & Co., Ltd., Osaka, Japan) were measured
n blood samples collected during hospitalization
ithin 2 months before the diagnostic cardiac
atheterization procedure in all 100 patients. A
TnT serum concentration ≥0.01 ng/ml was clas-
iﬁed as elevated, since it is <0.01 ng/ml in
9th percentile of healthy subjects [12,16]. LVEF
alculated by Simpson’s modiﬁed method, and
V end-diastolic diameter (EDD) were measured
chocardiographically. Diabetes mellitus (DM) was
eﬁned as a fasting serum glucose ≥126mg/dl,
on-fasting serum glucose >200mg/dl, or use of an
nti-diabetic medication. Hypertension was deﬁned
s a resting systolic blood pressure ≥140mmHg,
r diastolic blood pressure ≥90mmHg, or use
f an antihypertensive medication. Hypercholes-
erolemia was deﬁned as a total cholesterol
240mg/dl, or use of a statin.
ollow-up data collection and deﬁnition of
dverse cardiac events
he patients were followed until March 2008.
he latest available echocardiographic measure-
ents and cTnT and BNP serum concentrations
ere used as follow-up data. The echocardio-
raphic change was classiﬁed as improved when
1) LVEF had increased by ≥5% and (2) LVEDD had
ecreased by ≥5mm from baseline. Adverse car-
iac events included sudden death, death from
F, and re-hospitalization for management of car-
iac decompensation with pulmonary edema and
rthopnea, requiring the emergent administration
f intravenous diuretics, inotropes, or vasodilators.
tatistical analysisichotomous variables by Chi-square analysis. A
ogistic regression analysis was performed to exam-
ne the relationship between (1) elevated cTnT
nd baseline characteristics, and (2) changes in
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cTnT as a surrogate marker in heart failure
chocardiographic cardiac function and clinical
ariables including cTnT and BNP concentrations.
dds ratios and 95% conﬁdence intervals were cal-
ulated. Adverse cardiac event-free survival curves
ere constructed by the Kaplan—Meier method,
nd compared by log—rank test. Cox regression
nalysis was used to evaluate the prognostic value
f each variable. Hazard ratios and 95% conﬁdence
ntervals were calculated. Variables that were sig-
iﬁcant in the single variable analysis were included
n the multiple variable models, and a stepwise for-
ard multiple variable analysis was carried out to
dentify independent correlations. A p value <0.05
as considered signiﬁcant. The JMP® for Windows
tatistical package, Version 5.1 (SAS Institute Inc.,
ary, NC, USA) was used for all analyses.
esults
aseline characteristics and cTnT
oncentrations
mong the 100 patients included in this analysis, 30
30%) had a serum cTnT concentration ≥0.01 ng/ml.
ompared with patients whose baseline cTnT con-
entration was <0.01 ng/ml, patients with elevated
TnT (a) were in a signiﬁcantly higher mean New
ork Heart Association (NYHA) functional class, (b)
ad a lower mean hemoglobin, (c) had higher serum
reatinine and BNP concentrations, and higher pul-
onary capillary wedge pressure (PCWP) at the
ime of diagnostic catheterization, and (d) were
igniﬁcantly more likely to be diabetic (Table 1).
The variables listed in Table 1 were tested by
ogistic regression analysis in search of correlates
f elevated cTnT (Table 2). NYHA functional class
nd a history of DM, as dichotomous variables, and
emoglobin, creatinine, PCWP and BNP concentra-
ion, as continuous variables, were correlated with
erum cTnT concentrations at baseline. By unad-
usted and adjusted multiple variable analysis, a
istory of DM, serum creatinine concentration, and
CWP were independent predictors of baseline
TnT.
chocardiographic changes in cardiac
unction and follow-up cTnT versus
ollow-up BNP measurements
ut of the 100 consecutive patients, 7 were lost
o follow-up and contributed no data to this anal-
sis. The latest echocardiographic observations in
he 93 remaining patients were made at a mean
ollow-up of 33.0± 18.4 months, and the latest
easurements of serum cTnT and BNP concen-
a
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rations at 37.6± 21.4 months. A ≥5% increase
n LVEF was observed in 72 patients, a ≥5mm
ecrease in LVEDD was observed in 53 patients,
nd both were observed in 52 patients. A logis-
ic regression analysis was performed in search of
orrelates of improvements, in echocardiographic
ardiac function, including all variables listed in
able 1, and the follow-up measurements of cTnT
nd BNP. By single variable analysis, the long-term
chocardiographic improvements, were correlated
ith (a) diagnosis of HF for >1 year, (b) follow-
p cTnT and BNP serum concentrations, and (c)
se of a beta-adrenergic blocker during follow-up
Table 3), though were correlated with baseline
easurements of neither cTnT (p = 0.922) nor BNP
p = 0.121) concentrations. By unadjusted multi-
le variable analysis, follow-up concentrations of
TnT and BNP were independent predictors of
chocardiographic improvements; however, after
djustment for covariables, follow-up cTnT con-
entration emerged as the single independent
redictor (Table 3).
dverse cardiac event-free rate and
ollow-up cTnT versus follow-up BNP and
chocardiographic improvement in cardiac
unction
uring a follow-up of 40.6± 20.6 months, 23
dverse cardiac events occurred, including 5 deaths
ue to HF, and 1 sudden death. Kaplan—Meier sur-
ival curves were constructed according to the
aseline and follow-up measurements of cTnT and
NP. Patients whose initial BNP concentration was
bove versus below the median value of 460 pg/ml
ad similar adverse cardiac event-free survivals
Fig. 1A). In contrast, patients whose follow-up
NP concentration was above the median value of
5.4 pg/ml had a signiﬁcantly lower adverse cardiac
vent-free survival than patients whose follow-
p BNP concentration was ≤65.4 pg/ml (Fig. 1B).
atients whose serum cTnT concentration was
0.01 ng/ml at baseline (Fig. 2A) or during long-
erm follow-up (Fig. 2B) had a signiﬁcantly higher
dverse cardiac event-free survival than patients
hose cTnT concentration was ≥0.01 ng/ml.
By single variable Cox regression analysis, NYHA
unctional class III or IV, old age, a history of HF
or >1 year, and elevated follow-up cTnT and BNP
oncentrations were positive predictors, whereas
n echocardiographic improvement in cardiac func-
ion was a negative predictor of adverse cardiac
vents (Table 4). By multiple variable analyses,
ollow-up cTnT and BNP serum concentrations
ere independent predictors of adverse cardiac
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Table 1 Patient characteristics and baseline cardiac troponin T (cTnT).
All patients (n = 100) Baseline cTnT pa
≥0.01 (n = 30) <0.01 (n = 70)
Age, years 60.7± 12.3 61.9± 13.2 60.2± 11.9 0.533
Women/men 36/64 11/19 25/45 0.999
NYHA functional class I+II 45/100 6/30 39/70 0.001
Height, cm 160.4± 8.9 160.4± 10.1 160.4± 8.5 0.975
Body weight, kg 60.8± 15.4 61.6± 17.1 60.5± 14.7 0.751
Atrial ﬁbrillation at baseline 39/100 8/30 31/70 0.120
History of
Hypertension 47/100 13/30 34/70 0.667
Hyperlipidemia 15/100 5/30 10/70 0.765
Diabetes mellitus 17/100 9/30 8/70 0.039
Heart failure for >1 year 27/100 11/30 16/70 0.218
Hemoglobin, g/dl 13.9± 1.8 13.3± 2.1 14.1± 1.7 0.037
Serum creatinine, mg/dl 0.97± 0.31 1.14± 0.41 0.89± 0.22 0.0003
Cholesterol, mg/dl 185± 37 178± 38 188± 36 0.180
B-type natriuretic peptide, pg/ml 594± 615 875± 813 474± 463 0.002
Catheterization procedure
Aortic blood pressure, mmHg
Systolic 127± 24 125± 20 128± 26 0.558
Diastolic 75± 14 72± 12 76± 15 0.218
Heart rate, bpm 83± 17 81± 12 84± 19 0.530
Left ventricular ejection fraction, % 32.6± 10.5 29.5± 11.2 33.9± 10.0 0.054
Pulmonary capillary wedge pressure, mmHg 11.4± 7.3 15.4± 8.4 9.7± 6.0 0.0003
Cardiac index, l/min per m2 3.0± 0.8 2.9± 0.9 3.0± 0.7 0.490
Echocardiographic measurements
Left ventricular ejection fraction, % 35.1± 8.9 34.0± 9.2 35.5± 8.9 0.454
Left ventricular diastolic diameter, mm 60.9± 6.8 62.8± 7.1 60.2± 6.6 0.084
Medications during follow-up
ACE inhibitor, ARB 83/100 26/30 57/70 0.576
Beta-adrenergic blocker 76/100 23/30 53/70 0.999
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BValues are means± S.D. or numbers of observations. NYHA, N
ARB, angiotensin receptor blocker.
a ≥0.01 ng/ml versus <0.01 ng/ml baseline cTnT concentrat
events. However, after adjustment for covariables,
including echocardiographic improvement in car-
diac function, BNP was no longer predictive, and
follow-up cTnT concentration remained as a single
independent predictor of adverse cardiac events.
Discussion
Alterations in the biology of cardiac myocytes is the
primary event that initiates the process of cardiac
remodeling, itself believed to be a major surro-
gate marker for adverse cardiac events in patients
with HF [17—20]. This study retrospectively exam-
ined the correlation between elevated serum cTnT
concentrations and (a) baseline patient charac-
teristics and hemodynamic measurements made
T
c
w
tork Heart Association; ACE, angiotensin-converting enzyme;
uring baseline cardiac catheterization, (b) long-
erm changes in echocardiographic cardiac function
ith BNP concentrations, and (c) long-term rates
f adverse cardiac events with BNP concentrations
nd echocardiographic changes. Since coronary
rtery stenoses may increase the serum concen-
ration of cTnT and coronary interventions may
nﬂuence the echocardiographic changes that take
lace over time, patients with ischemic heart dis-
ase were excluded from this analysis.
aseline characteristics and cTnThe clinical and hemodynamic factors that are asso-
iated with elevated baseline cTnT concentrations
ere previously unknown. This analysis revealed
hat a history of DM, an elevated serum creatinine,
cTnT
as
a
surrogate
m
arker
in
heart
failure
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Table 2 Correlates of elevated baseline serum cardiac troponin T (cTnT) in single and multiple variable logistic regression analysis.
Analysis
Single variable Multiple variable
Unadjusted Adjusteda Adjustedb
NYHA functional class I or II 0.19 (0.07—0.54) p = 0.0017 p = 0.080 p = 0.076 -
History of diabetes mellitus 3.3 (1.1—9.7) p = 0.0284 4.2 (1.1—16.5) p = 0.035 5.6 (1.3—23.5) p = 0.0189 7.5 (1.5—37.7) p = 0.014
Hemoglobin (g/dl) 0.77 (0.60—0.99) p = 0.0446 p = 0.057 p = 0.108 —
Serum creatinine (mg/dl) 13.9 (2.8—69.4) p = 0.0013 12.9 (1.9—88.0) p = 0.0087 22.1 (2.4—204.9) p = 0.0063 25.9 (1.8—364.9) p = 0.0157
Pulmonary capillary wedge
pressure, mmHg
1.12 (1.04—1.20) p = 0.0017 1.10 (1.01—1.19) p = 0.023 1.09 (1.01—1.19) p = 0.022 1.12 (1.01—1.23) p = 0.0214
B-type natriuretic peptide,
pg/ml
1.001 (1.000—1.002) p = 0.0077 — — —
Values are odds ratios (95% conﬁdence intervals).
a For age, gender.
b For age, gender, height, body weight, atrial ﬁbrillation, left ventricular ejection fraction, hemoglobin, and New York Heart Association (NYHA) functional class.
Table 3 Factors correlated with echocardiographic improvements in cardiac function during long-term follow-up.
Analysis
Single variable Multiple variable
Unadjusted Adjusteda Adjustedb
History of heart failure >1 year 0.37 (0.14—0.94) p = 0.037 — — —
Follow-up cTnT ≥0.01, ng/ml 0.08 (0.01—0.41) p = 0.0021 0.15 (0.02—0.79) p = 0.0255 0.16 (0.03—0.87) p = 0.0343 0.10 (0.01—0.68) p = 0.019
Follow-up BNP >median value (65.4 pg/ml) 0.21 (0.09—0.53) p = 0.0007 0.32 (0.12—0.85) p = 0.0222 p = 0.106 p = 0.090
Use of beta-adrenergic blocker 3.09 (1.09—8.71) p = 0.0324 p = 0.0781 p = 0.077 —
Values are odds ratios (95% conﬁdence intervals). cTnT, cardiac troponin T; BNP, B-type natriuretic peptide.
a For age and gender.
b For age, gender, hemoglobin, serum creatinine, left ventricular ejection fraction, New York Heart Association (NYHA) functional class, pulmonary capillary wedge pressure, history
of heart failure, and use of beta-adrenergic blocker, angiotensin-converting enzyme inhibitor, and angiotensin receptor blocker.
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Figure 1 (A) Adverse cardiac event-free survivals
according to baseline serum B-type natriuretic pep-
tide (BNP) concentration <460 pg/ml (n = 46) versus
Figure 2 (A) Adverse cardiac event-free survivals
according to baseline serum cardiac troponin T (cTnT)
concentration <0.01 ng/ml (n = 64) versus ≥0.01 ng/ml
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f≥460 pg/ml (n = 47). (B) Adverse cardiac event-free
survivals according to last serum BNP concentration
<65.4 pg/ml (n = 46) versus ≥65.4 pg/ml (n = 47).
and elevated PCWP were independent predictors
of elevated cTnT after adjustment for several con-
founding variables. Our previous analysis of 2 other
databases showed no correlation between baseline
concentrations of cTnT and LVEF [9,21]. Similarly,
Horwich et al. observed no correlation between
elevated concentrations of cTnI and baseline LVEF;
though found a correlation with PCWP [10]. Also in
support of our observations, Wallace et al. reported
the results of a multiple variable logistic regres-
sion analysis, which revealed that LV hypertrophy,
HF, DM, and chronic kidney disease were indepen-
dently associated with elevated cTnT in the general
population [22].
The mechanism(s) of cTnT release in patients
with HF remains unclear. We and other investiga-
tors have previously found correlations between
elevated serum cTnT and elevated BNP, renin,
norepinephrine, and C-reactive protein serum
concentration, suggesting that myocardial load,
activation of the rennin—angiotensin—aldosterone
and autonomic sympathetic systems, and inﬂam-
mation are causes of myocyte injury in patients
with chronic HF [12,21]. In patients with acutely
decompensated HF, hypotension upon admission
to the hospital and the administration of intra-
m
W
tn = 29). (B) Adverse cardiac event-free survivals accord-
ng to last serum cTnT concentration <0.01 ng/ml (n = 78)
ersus ≥0.01 ng/ml (n = 15).
enous inotropes may also cause further increases
n cTnT [23,24]. In this analysis, however, renin,
orepinephrine, and C-reactive protein measure-
ents were not available.
While the mechanisms of cTnT elevation in
atients with renal insufﬁciency are also unre-
olved, elevation of cTnT in this clinical setting
as prognostic implications [25]. A recent study
ound that cTnT is fragmented into molecules small
nough to be excreted by the kidney [26]. There-
ore, the serum concentrations of cTnT might be
artially determined by renal clearance. Moreover,
M increases the risk of HF regardless of the pres-
nce or absence of underlying coronary artery dis-
ase, and may be a cause of cardiomyopathy [27].
eticulous attention to these background factors
ight be important therapeutic goals, with a view
o lower serum cTnT concentrations and attenuate
yocyte injury associated with cardiac remodeling.
mprovements in echocardiographic cardiac
unction and follow-up cTnT versus BNP
easurements
e have hypothesized that elevated serum concen-
rations of cTnT are a marker of myocyte injury
cTnT
as
a
surrogate
m
arker
in
heart
failure
227
Table 4 Factors correlated with adverse cardiac events during long-term follow-up.
Analysis
Single variable Multiple variable
Unadjusted Adjusteda Adjustedb Adjustedc
NYHA functional class
III or IV at baseline
3.2 (1.2—8.7) p = 0.019 — — — —
Age 1.06 (1.02—1.11) p = 0.002 — — — —
History of heart failure
>1 year
3.15 (1.38—7.15) p = 0.006 — — — —
Echocardiographic
changes
0.12 (0.04—0.37) p = 0.0002 — — — —
Follow-up cTnT
≥0.01 ng/ml
11.4 (4.9—26.9) p < 0.0001 7.1 (2.8—17.6) p < 0.0001 6.4 (2.5—16.5) p < 0.0001 7.9 (2.5—24.8) p = 0.0004 5.6 (1.7—18.4) p = 0.0046
Follow-up BNP
>65.4 pg/ml
8.3 (2.4—28.0) p = 0.0006 4.6 (1.2—16.8) p = 0.0183 3.9 (1.04—14.6) p = 0.042 4.9 (1.04—23.7) p = 0.043 p = 0.103
Values are hazard ratios (95% conﬁdence intervals). cTnT, cardiac troponin T; BNP, B-type natriuretic peptide.
a For age and gender.
b For age, gender, hemoglobin, serum creatinine, left ventricular ejection fraction, New York Heart Association (NYHA) functional class, pulmonary capillary wedge pressure, history
of heart failure, and use of beta-adrenergic blocker, angiotensin-converting enzyme inhibitor, and angiotensin receptor blocker.
c For all covariables listed under b improvements in echocardiography.
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[7], and studies performed by us and by oth-
ers have found a negative correlation between
cTnT elevation and long-term echocardiographic
improvements in cardiac function [9—11]. However,
no study has compared the correlation between
echocardiographic changes and elevated cTnT ver-
sus elevated BNP concentrations. On the other
hand, a correlation has been reported between
long-term changes in BNP and long-term echocar-
diographic changes in cardiac function [5,6]. In
this study, follow-up cTnT and BNP concentra-
tions were both independently associated with
echocardiographic changes. However, after adjust-
ments for confounding variables, follow-up cTnT
emerged as the only signiﬁcant predictor. It has
been reported that the combination measurement
of both cTnT and BNP can identify patients at high-
est risk [2,7,10,15,28,29]. In this study, the odds
ratio of both elevated cTnT and BNP at follow-up
for the echocardiographic change was the low-
est [unadjusted: 0.042 (0.005—0.340), p = 0.0029;
adjusted by confounding variables listed in Table 3:
0.031 (0.003—0.366), p = 0.0058].
Adverse cardiac event-free rate and
follow-up cTnT versus BNP and
improvements in echocardiographic cardiac
function
Before the use of BNP, improvements in echocar-
diographic measurements of cardiac function over
time were considered a surrogate marker of
adverse cardiac events [19]. BNP is now widely
used for the diagnosis and risk stratiﬁcation of
HF [1,2] and, since changes in BNP over time
correlate with rates of adverse cardiac events
[3,4], it is considered a surrogate marker of such
events. Furthermore, both cTnT and BNP are
independent predictors of adverse cardiac events
in patients suffering from HF [2,7,10,15,28,29].
However, the predictive power of follow-up mea-
surements of cTnT has not been compared with
that of follow-up measurement of BNP or long-
term improvements in echocardiographic cardiac
function. In this study, follow-up cTnT, follow-
up BNP concentrations, and echocardiographic
changes were signiﬁcantly correlated with long-
term rates of adverse cardiac events in the single
variable analysis, and follow-up cTnT and BNP con-
centrations were both independent predictors of
adverse cardiac events in the multiple variable
analysis. However, after adjustment for covari-
ables, including echocardiographic improvement in
cardiac function, BNP was no longer predictive,
and follow-up cTnT concentration remained as aY. Sato et al.
ingle independent predictor of adverse cardiac
vents. The hazard ratio of both elevated cTnT
nd BNP at follow-up was the highest [unadjusted:
4.5 (6.0—35.1), p < 0.0001; adjusted by confound-
ng variables listed in Table 4: 7.6 (2.2—25.7),
= 0.0010].
In conclusion, in patients with HF and non-
schemic heart disease, follow-up cTnT was a
owerful predictor of changes in echocardiographic
ardiac function and adverse cardiac events. There-
ore, serial measurements of cTnT might be a
owerful surrogate marker of HF.
tudy limitations
his study was conducted at a single institution
nd included a relatively small patient popula-
ion. Therefore, creatinine was not a signiﬁcant
redictor of echocardiographic change and long-
erm prognosis. Furthermore, since our analysis,
ased on a diagnostic catheterization database,
as retrospective, the timing of serial echocardio-
raphic observations and measurements of cTnT
nd BNP was not systematically planned, and no
ttempt was made to examine the effects of ther-
py. Although echocardiographic parameters such
s E/A and Tei index are powerful prognostic indica-
ors [30—32], these parameters were not available.
inally, cTnT was treated as a dichotomous variable
ecause the 3rd generation assay cannot measure
oncentrations <0.01 ng/ml. However, the upcom-
ng, highly sensitive, next-generation cTnT assay
12,33] will enable the measurement of risk as a
TnT concentration-dependent factor, and exam-
ne the inﬂuence of proportional changes in cTnT
n echocardiographic changes and adverse cardiac
vents.
cknowledgment
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